Stemmer, Salomon M.
Steiner, Mariana
Rizel, Shulamith
Soussan-Gutman, Lior
Ben-Baruch, Noa
Bareket-Samish, Avital
Geffen, David B.
Nisenbaum, Bella
Isaacs, Kevin
Fried, Georgeta
Rosengarten, Ora
Uziely, Beatrice
Svedman, Christer
McCullough, Debbie
Maddala, Tara
Klang, Shmuel H.
Zidan, Jamal
Ryvo, Larisa
Kaufman, Bella
Evron, Ella
Karminsky, Natalya
Goldberg, Hadassah
Shak, Steven
Liebermann, Nicky
Article History
Received: 1 March 2017
Revised: 19 June 2017
Accepted: 22 June 2017
First Online: 8 September 2017
Competing Interests
: Dr. Stemmer reports receiving grant funding from Teva and travel expenses (flights, accommodation) from Genomic Health, Inc. Dr. Soussan-Gutman reports being employed by and holding stock options in Teva Pharmaceutical Industries Ltd. Dr. Bareket-Samish reports being a consultant for Teva Pharmaceutical Industries Ltd. and Genomic Health Inc. Dr. Ben Baruch reports receiving personal fees from Genomic Health Inc (for participating in the Speaker’s Bureau program). Dr. Rosengarten reports receiving payments for lectures and grants for traveling to conferences from Teva Pharmaceutical Industries Ltd. Dr. Svedman, Ms. McCullough, Dr. Maddala, and Dr. Shak report being employed by and stock ownership in Genomic Health, Inc. Dr. Shak also reports having multiple patents for the Onco<i>type</i> DX assay (for which all rights were assigned to Genomic Health, Inc.). Drs. Steiner, Rizel, Geffen, Nisenbaum, Isaacs, Fried, Uziely, Klang, Zidan, Ryvo, Kaufman, Evron, Karminsky, Goldberg, and Liebermann report no conflict of interest.